C4 Therapeutics to present cemsidomide biomarker data at myeloma meeting

September 3, 2026 7:00 AM

C4 Therapeutics, Inc. (Nasdaq: CCCC) announced it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found